Compare LyondellBasell Industries NV (LYB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs TG Therapeutics Inc — how do they compare? LyondellBasell Industries NV trades at $62.27 (market cap $19.75B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: LyondellBasell Industries NV is far larger — about 2.4× TG Therapeutics Inc's market cap, and LyondellBasell Industries NV pays a 6.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LYB | TGTX | |
|---|---|---|
Market Cap | $19.75B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $59.06 |
52-Week Low | $42.28 | $26.39 |
Enterprise Value | $31.37B | $8.50B |
Dividend Yield | 6.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $61.19, up 3.38% today, with a bullish technical signal and strong analyst consensus price target of $72.56. Recent earnings show volatility with Q1 2026 beating expectations, while Q4 2025 missed. The company maintains positive cash flow and recently announced a $0.69 dividend. Revenue has declined from $50.5B in 2022 to $30.2B in 2025, with net income turning negative at -$745M. News highlights include partnerships for sustainable packaging and anticipation of strong Q2 2026 earnings.
LYB presents a mixed outlook: potential upside exists from expected earnings recovery and strategic shifts toward high-margin polymers, but risks include declining revenue, negative profitability, and high debt. Investors should weigh the bullish analyst sentiment against fundamental challenges in the chemical sector.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
